-- Lilly's Testosterone Lotion Gains U.S. Approval, Pushing Acrux to Record
-- B y   S i m e o n   B e n n e t t
-- 2010-11-24T21:13:22Z
-- http://www.bloomberg.com/news/2010-11-24/testosterone-lotion-approval-in-the-u-s-propels-acrux-shares-to-record.html
Acrux Ltd. , the developer of an
underarm testosterone lotion with  Eli Lilly & Co. , rose to a
record in Australian trading after the treatment was approved
for sale in the U.S.  Acrux  rose 9.1 percent to A$3.36 as of the 4:10 p.m. close
in Sydney, the highest level since the shares listed in
September 2004. The stock earlier surged as much as 18 percent.  The U.S. Food and Drug Administration approved the Axiron
lotion for men with certain conditions associated with a
deficiency or absence of testosterone, Melbourne-based Acrux and
Lilly said in a statement dated Nov. 23.  Acrux will receive a payment of $87 million from Lilly,
which bought the rights to the drug in March. The Australian
company will get royalties and further payments of as much as
$195 million from the Indianapolis-based company. Acrux
previously said it plans to pay its first  dividend  to
shareholders in early 2011.  Lilly, based in Indianapolis, increased 14 cents, or less
than a percent, to $34.22 at 4 p.m. in New York Stock Exchange
composite  trading .  To contact the reporter on this story:
 Simeon Bennett  in Singapore at 
 sbennett9@bloomberg.net .  To contact the editor responsible for this story:
Jason Gale at   j.gale@bloomberg.net . 